August 15, 2022Open Access

Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin’s lymphoma (NHL) and has high heterogeneity. Approximately 30%–50% of patients develop relapsed/refractory (R/R) disease, which remains a major cause of mortality11–32. In recent years, a variety of novel therapies

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Qiu et al. (Mon,) studied this question.

synapsesocial.com/papers/6a096a9487ad1657d25147c1 https://doi.org/https://doi.org/10.20892/j.issn.2095-3941.2022.0403

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Subcutaneous epcoritamab + R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT): Preliminary phase 1/2 results.2022 · 11 citations
2Two-year follow-up result of RELIANCE study, a multicenter phase 2 trial of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma.2022 · 3 citations
3Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab2015 · 62 citations
4First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.2022 · 19 citations
5Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma2018 · 4,064 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo